# Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

> **NCT03544723** · PHASE2 · UNKNOWN · sponsor: **MultiVir, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** Ad-p53

## Key facts

- **NCT ID:** NCT03544723
- **Lead sponsor:** MultiVir, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03544723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03544723, "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03544723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*